Pharmaceutical firm Gilead has recently taken over German biotech startup Tubulis for $3.2 billion (£2.3 billion). This agreement allowed Gilead to obtain two of Tubulis’ antibody–drug conjugates (ADCs) which have demonstrated promising outcomes in initial clinical trials. One ADC addresses platinum-resistant ovarian cancer, while the other is directed at several types of solid tumors. Central […]
Read More